New hope for rare muscle disease: drug eases daily struggles in chinese patients
NCT ID NCT06764160
First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tested a drug called eculizumab in 15 Chinese adults with refractory generalized myasthenia gravis (gMG), a condition causing severe muscle weakness. The goal was to see if the drug could improve patients' ability to perform daily activities and reduce muscle weakness over 26 weeks. All participants received the drug, and researchers measured changes in symptom scores and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Changchun, 130021, China
-
Research Site
Fuzhou, 350001, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510620, China
-
Research Site
Qingdao, 266035, China
-
Research Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.